BioCryst Pharmaceuticals (NASDAQ:BCRX) Given New $17.00 Price Target at Needham & Company LLC
BioCryst Pharmaceuticals (NASDAQ:BCRX – Free Report) had its price target lifted by Needham & Company LLC from $15.00 to $17.00 in a report issued on Tuesday,Benzinga reports. The firm currently has a buy rating on the biotechnology company’s stock. Other equities research analysts have also issued research reports about the stock. Wedbush assumed coverage on […]
BioCryst Pharmaceuticals (NASDAQ:BCRX – Free Report) had its price target lifted by Needham & Company LLC from $15.00 to $17.00 in a report issued on Tuesday,Benzinga reports. The firm currently has a buy rating on the biotechnology company’s stock. Other equities research analysts have also issued research reports about the stock. Wedbush assumed coverage on […]
